ESSA PHARMA INC's ticker is EPIX and the CUSIP is 29668H708. A total of 72 filers reported holding ESSA PHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,924,491 | +23.7% | 4,182,683 | +8.1% | 0.00% | 0.0% |
| Q2 2023 | $10,449,216 | +13.3% | 3,870,080 | +24.6% | 0.00% | 0.0% |
| Q1 2023 | $9,222,489 | +82.4% | 3,105,215 | +54.8% | 0.00% | 0.0% |
| Q4 2022 | $5,056,322 | +31.9% | 2,006,477 | -4.7% | 0.00% | 0.0% |
| Q3 2022 | $3,833,000 | -66.8% | 2,106,019 | -42.6% | 0.00% | -50.0% |
| Q2 2022 | $11,559,000 | +20.6% | 3,669,680 | +136.7% | 0.00% | +100.0% |
| Q1 2022 | $9,581,000 | +13394.4% | 1,550,530 | +30707.3% | 0.00% | – |
| Q4 2021 | $71,000 | -92.2% | 5,033 | -95.6% | 0.00% | – |
| Q3 2021 | $912,000 | -93.6% | 113,981 | -77.1% | 0.00% | -100.0% |
| Q2 2021 | $14,194,000 | -14.7% | 496,809 | -13.3% | 0.00% | 0.0% |
| Q1 2021 | $16,644,000 | +198.9% | 572,967 | +22.8% | 0.00% | +100.0% |
| Q4 2020 | $5,568,000 | +132.7% | 466,714 | +34.6% | 0.00% | – |
| Q3 2020 | $2,393,000 | +206.8% | 346,819 | +175.5% | 0.00% | – |
| Q2 2020 | $780,000 | +1757.1% | 125,865 | +1558.5% | 0.00% | – |
| Q4 2019 | $42,000 | – | 7,589 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soleus Capital Management, L.P. | 4,223,799 | $26,103,000 | 3.37% |
| MPM BioImpact LLC | 660,892 | $4,084,000 | 1.10% |
| BVF INC/IL | 3,695,629 | $22,839,000 | 0.91% |
| Omega Fund Management, LLC | 328,196 | $2,028,000 | 0.42% |
| Eventide Asset Management | 4,170,259 | $25,772,000 | 0.40% |
| Frazier Life Sciences Management, L.P. | 692,910 | $4,282,000 | 0.36% |
| Bellevue Group AG | 5,034,814 | $31,115,000 | 0.36% |
| RTW INVESTMENTS, LP | 2,637,192 | $16,298,000 | 0.34% |
| Avidity Partners Management LP | 2,460,000 | $15,203,000 | 0.32% |
| Rhenman & Partners Asset Management AB | 410,923 | $2,540,000 | 0.25% |